Zika Virus Disease – A Complete Patient‑Friendly Guide

Overview

Zika virus disease is an acute, usually mild, febrile illness caused by the Zika virus, a member of the Flaviviridae family. The virus is primarily transmitted to humans through the bite of infected Aedes mosquitoes (most commonly Aedes aegypti and Aedes albopictus). Since its first identification in a rhesus monkey in the Zika forest of Uganda in 1947, the disease has spread globally, with major outbreaks reported in the Pacific Islands (2013‑2014) and the Americas (2015‑2016).

Who it affects: Anyone can be infected, but the most clinically significant groups are pregnant women (due to the risk of congenital Zika syndrome), travelers to endemic regions, and people living in areas where the vector mosquito thrives. The disease is most common in tropical and subtropical regions of Africa, Asia, the Pacific, and the Americas.

Prevalence: According to the World Health Organization (WHO), more than 87,000 suspected cases were reported worldwide between 2015 and 2020, with the highest concentration in Brazil, Colombia, and Mexico. In the United States, the CDC recorded 5,000+ travel‑related cases from 2016‑2022, though local transmission has been limited to a few Florida and Texas counties.^[1][2]

Symptoms

Zika infection is often asymptomatic (≈80% of cases). When symptoms do appear, they typically begin 3‑14 days after exposure and last 2‑7 days. Common and less common manifestations include:

• Fever – low‑grade (usually <38 °C/100.4 °F).
• Rash – maculopapular, often starting on the face and spreading to the trunk and limbs.
• Conjunctivitis – non‑purulent (pink eye) without discharge.
• Arthralgia – joint pain, especially in the hands and feet.
• Myalgia – muscle aches.
• Headache – typically mild to moderate.
• Fatigue – generalized tiredness.
• Retro‑orbital pain – pain behind the eyes (less common).
• Gastrointestinal symptoms – nausea, vomiting, or abdominal pain (rare).

In pregnant women, the virus can cross the placenta, leading to fetal infection. While most infants are born without obvious abnormalities, some develop:

• Microcephaly
• Intracranial calcifications
• Eye abnormalities (e.g., chorioretinal scarring)
• Arthrogryposis (joint contractures)

These congenital effects are collectively termed Congenital Zika Syndrome (CZS).^[3]

Causes and Risk Factors

Primary cause

The Zika virus is an RNA virus transmitted mainly by the bite of an infected Aedes mosquito. The virus replicates in the mosquito’s salivary glands and is injected into the human host during feeding.

Other transmission routes

• Sexual transmission – virus can be present in semen for up to 6 months after infection.
• Maternal‑fetal transmission – transplacental spread during pregnancy.
• Blood transfusion – rare, but documented in some outbreak settings.

Risk factors

• Living in or traveling to areas with active Aedes mosquito populations.
• Pregnancy or planning pregnancy while in endemic zones.
• Engaging in unprotected sexual activity with a partner who has traveled to an endemic area.
• Outdoor occupations or activities during peak mosquito activity (dawn & dusk).
• Limited access to mosquito control measures (e.g., screens, repellents).

Diagnosis

Because Zika symptoms overlap with dengue, chikungunya, and other arboviruses, laboratory confirmation is essential.

Laboratory tests

1. Reverse‑transcription polymerase chain reaction (RT‑PCR) – Detects viral RNA in serum, urine, or saliva. Most reliable within the first 7‑10 days of symptom onset.
2. Serology (IgM ELISA) – Detects Zika‑specific IgM antibodies. Useful after the acute phase (7‑14 days) but can cross‑react with other flaviviruses; confirmatory plaque reduction neutralization test (PRNT) may be required.
3. Urine testing – Zika RNA can be detected in urine for up to 14 days, extending the diagnostic window.

Imaging (for pregnant women)

If fetal infection is suspected, obstetric ultrasound can reveal microcephaly, ventriculomegaly, or intracranial calcifications. In some cases, fetal MRI provides more detailed assessment.

Clinical criteria

In resource‑limited settings, a combination of epidemiologic exposure (travel or residence in an endemic area) plus compatible symptoms may be used to make a presumptive diagnosis, but confirmatory testing is recommended whenever possible.

Treatment Options

There is no specific antiviral therapy for Zika virus disease. Management focuses on supportive care and symptom relief.

Medications

• Acetaminophen (paracetamol) – First‑line for fever and pain. Avoid NSAIDs (e.g., ibuprofen) until dengue is ruled out because of bleeding risk.
• Antihistamines – May help with itching from rash.
• Hydration – Oral rehydration solutions or increased fluid intake to prevent dehydration.

Procedures

• None specific; however, pregnant women with confirmed infection should receive close obstetric monitoring (ultrasound every 4‑6 weeks).

Lifestyle & supportive measures

• Rest in a cool, comfortable environment.
• Apply cool compresses to reduce rash discomfort.
• Use a soft toothbrush and avoid spicy or acidic foods if oral ulcers develop.

Living with Zika Virus Disease

Most people recover fully within a week, but the following tips can help manage daily life and reduce anxiety, especially for pregnant individuals.

• Track symptoms – Keep a simple diary of temperature, rash progression, and any new neurological signs.
• Stay hydrated – Aim for at least 2‑3 L of fluid daily unless contraindicated.
• Protect yourself from mosquito bites even after symptoms resolve, as the virus can persist in blood/urine for several days.
• Sexual precautions – Use condoms or abstain for at least 8 weeks after symptom onset (or 12 weeks for pregnant partners) to prevent sexual transmission.^[4]
• Pregnancy monitoring – Attend all scheduled prenatal visits; discuss Zika testing with your obstetrician.
• Psychological support – Anxiety about fetal outcomes is common; consider counseling or support groups.

Prevention

Because no vaccine is currently licensed for general use (clinical trials are ongoing), prevention relies on vector control and personal protective measures.

Vector‑control strategies

• Eliminate standing water (flower pots, tires, buckets) where mosquitoes breed.
• Use indoor residual spraying or larvicides in high‑risk neighborhoods.
• Install window and door screens; repair any holes.
• Encourage community clean‑up campaigns.

Personal protection

• Insect repellent – Apply EPA‑registered repellents containing DEET (≥30%), picaridin, IR3535, or oil of lemon eucalyptus. Reapply every 2‑3 hours.
• Protective clothing – Long‑sleeved shirts, long pants, and socks, especially during dawn and dusk.
• Air‑conditioned or screened rooms – Reduce indoor mosquito exposure.
• Sexual precautions – Use condoms consistently if either partner has traveled to an endemic area.

Travel recommendations

• Pregnant women should consider postponing non‑essential travel to Zika‑active regions.
• If travel is unavoidable, follow the personal protection measures above and stay informed of local health advisories.

Complications

While most infections are mild, several serious complications can arise:

• Congenital Zika Syndrome – Permanent neurodevelopmental deficits, vision/hearing loss, and growth restriction.
• Guillain‑Barré Syndrome (GBS) – An autoimmune peripheral neuropathy that can cause muscle weakness and, in severe cases, respiratory failure. The incidence of GBS is estimated at 1‑2 per 10,000 Zika infections.^[5]
• Persistent viral shedding – Zika RNA may be detectable in semen for months, posing ongoing transmission risk.
• Psychological impact – Anxiety, depression, and stress related to pregnancy outcomes.

When to Seek Emergency Care

References

1. World Health Organization. Zika virus. WHO Fact Sheet. Updated 2023. https://www.who.int/news-room/fact-sheets/detail/zika-virus
2. Centers for Disease Control and Prevention. Travelers’ Health – Zika Virus. CDC, 2022. https://www.cdc.gov/zika/travel/index.html
3. National Institutes of Health. Congenital Zika Syndrome. NIH, 2021. https://www.nichd.nih.gov/health/topics/zika/conditioninfo/congenital
4. CDC. Sexual Transmission of Zika Virus. Updated 2023. https://www.cdc.gov/zika/sexual-transmission.html
5. Roth A, et al. Guillain‑Barré syndrome associated with Zika virus infection. New England Journal of Medicine. 2016;374:1635‑44.